Clinical trial · no report yet · Phase 2
NCT07832292
A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
- NCT07832292 ↗
- Recruiting
- Janssen Research & Development, LLC
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-label, Multicenter, Single-arm Trial of JNJ-101556143, an Androgen Receptor-targeted Regulated Induced Proximity Targeting Chimera (RIPTAC™) Therapeutic in Participants With Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Prostatic Neoplasms
- Interventions
- JNJ-101556143
- Arms
- JNJ-101556143 · Experimental
- Enrollment
- 100 (estimated)
- Primary outcomes
- Overall Response Rate (ORR)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Sep 16, 2026
- Primary completion
- May 17, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07832292 · updated Sep 25, 2026